Gelatin Patents (Class 424/456)
-
Patent number: 8617593Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: GrantFiled: February 15, 2013Date of Patent: December 31, 2013Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8617594Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: GrantFiled: February 26, 2013Date of Patent: December 31, 2013Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8613945Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: GrantFiled: November 26, 2012Date of Patent: December 24, 2013Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20130337059Abstract: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.Type: ApplicationFiled: March 5, 2013Publication date: December 19, 2013Applicant: Durect CorporationInventor: Durect Corporation
-
Publication number: 20130337060Abstract: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.Type: ApplicationFiled: March 5, 2013Publication date: December 19, 2013Applicant: Durect CorporationInventor: Durect Corporation
-
Patent number: 8609137Abstract: The present invention discloses a novel soft capsule of butylphthalide and a process for preparing the same. The soft capsule of butylphthalide is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil as the diluent in a weight ratio of about 1:0˜10. The capsule wall material is composed of a capsule wall matrix, a plasticizer and water in a weight ratio of 1:0.2˜0.4:0.8˜1.3. The soft capsule of butylphthalide described in the present invention can mask the strong and special flavor of butylphthalide, and overcome the difficulties associated with formulating oily active ingredient into other oral formulation. The disintegration time of the soft capsule satisfies the requirement of Pharmacopoeia of P.R. China.Type: GrantFiled: April 22, 2011Date of Patent: December 17, 2013Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC NBP Pharmaceutical Co., Ltd.Inventors: Jianqing Li, Min Bai, Wenmin Guo, Surui Chen, Liyun Liu, Guirong Zhou
-
Patent number: 8609138Abstract: Provided is a compound preparation including at least one selected from the group consisting of ?3 polyunsaturated fatty acids and pharmaceutically acceptable salts and esters thereof and at least one selected from the group consisting of statin compounds and pharmaceutically acceptable salts thereof. The compound preparation is in a form of a soft capsule having a capsule coating with a pH of 7.0 to 9.5. The compound preparation suppresses the decomposition of the statin compounds and/or the modification/insolubilization of the capsule coating. A medical use for the compound preparation, a method of manufacturing the compound preparation and a method of using the compound preparation are also provided.Type: GrantFiled: June 29, 2011Date of Patent: December 17, 2013Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Hirosato Fujii, Hiromitsu Ito, Motoo Yamagata
-
Patent number: 8609141Abstract: The present invention pertains to silver ion bearing carriers useful in treating monorrhagia of a mammalian uterus, comprising a physiologically inert, flexible earner, e.g., a coil, bearing a tissue cauterizing amount of a silver ion. Silver ions are delivered to the endometrium and cause necrosis of the endometrial tissue. The silver ions remaining within the uterine cavity can then be neutralized with a sodium chloride solution delivered to the uterus e.g., by catheter, and the carrier recovered from the uterus.Type: GrantFiled: September 1, 2009Date of Patent: December 17, 2013Assignee: Ablation Products LLCInventor: Robert S. Neuwirth
-
Publication number: 20130330405Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.Type: ApplicationFiled: August 13, 2013Publication date: December 12, 2013Applicant: Soft Gel Technologies, Inc.Inventor: Michael Fantuzzi
-
Publication number: 20130323304Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.Type: ApplicationFiled: August 1, 2013Publication date: December 5, 2013Applicant: Banner Pharmacaps, Inc.Inventors: Aqeel Fatmi, Tae Kyoung Kim, Karla E. Madrigal
-
Patent number: 8597666Abstract: A pharmaceutical formulation of compounds with low aqueous solubility and method of manufacture thereof. The formulation may include a pharmacologically active compound having low aqueous solubility and starch in the amount of greater than about 25 weight percent. A manufacturing method may include blending the active compound and starch, compressing the blend into a solid, comminuting the solid into granules, wetting the granules, drying the granules, and tabletting the dried granules to make a solid pharmaceutical formulation.Type: GrantFiled: October 28, 2011Date of Patent: December 3, 2013Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Ilan Zalit, Fanny Leska, Mali Kadosh, Dorit Marco, Yonit Messer-Triger
-
Patent number: 8586076Abstract: This invention relates to fat containing consumable food products comprising ?-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without ?-cyclodextrin. The invention also relates to methods for reducing the bioavailability of fats in fat containing food products without reducing caloric intake as determined by bomb calorimetry and to methods for increasing high density lipoproteins in a subject and reducing or controlling weight by administering the food products of this invention.Type: GrantFiled: December 30, 2011Date of Patent: November 19, 2013Assignee: SOHO Flordis International Pty LtdInventors: Joseph D. Artiss, Catherine Jen
-
Patent number: 8586094Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.Type: GrantFiled: May 2, 2003Date of Patent: November 19, 2013Assignee: Jagotec AGInventors: Michael Vachon, Mishra K. Awadesh, Robert A. Snow, Pol-Henri Guivarc'H
-
Patent number: 8586108Abstract: The present invention relates to plant extracts, specifically, the extracts of Chinese medicine Chenopodium ambrosioides L. and the composition comprising thereof. The extracts of Chinese medicine Chenopodium ambrosioides L. are prepared by conventional methods for the extraction of volatile oil, and can be used to treat Helicobacter Pylori-induced diseases of digestive system, such as gastritis, gastric ulcer, etc., with easy availability of raw materials, simple preparations, prominent effects, and less side-effect.Type: GrantFiled: December 21, 2012Date of Patent: November 19, 2013Assignee: Tasly Pharmaceutical Group Co., LtdInventors: Zhengliang Ye, Yonghong Zhu, Ying Zhao, Dekun Li, XiaoLi Zheng, Chongnian Luo, Feng Wei, GuangMing Zhang, JianMing Chen, Jun Gao, JunFeng Xiong
-
Publication number: 20130295172Abstract: Disclosed here are compositions comprising powdered hemp seed, an emulsifier/dispersant such as lecithin (particularly soya lecithin), cannabis, and optionally other additives and excipients. Also described are methods of making the compositions. The compositions may be used, for instance, in the treatment of pain and for their anti-emetic (anti-nausea and anti-vomiting) properties, as well as for the treatment of anorexia and appetite enhancement. Kits containing the compositions, arranged for proper sequential dosing, and optionally including instructions for use are also disclosed.Type: ApplicationFiled: March 28, 2013Publication date: November 7, 2013Inventor: Keith Gerald Freeman
-
Publication number: 20130287845Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.Type: ApplicationFiled: March 5, 2013Publication date: October 31, 2013Inventors: Su Il Yum, Grant Schoenhard, Arthur J. Tipton, John W. Gibson, John C. Middleton
-
Patent number: 8568773Abstract: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.Type: GrantFiled: June 24, 2009Date of Patent: October 29, 2013Assignee: Enzymotec Ltd.Inventors: Gai Ben Dror, Dorit Platt, Orly Farkash, Rassan Zuabi, Zohar Bar-On, Avidor Shulman, Dori Pelled, Yael Richter
-
Patent number: 8563042Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.Type: GrantFiled: June 25, 2010Date of Patent: October 22, 2013Assignee: EthypharmInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
-
Patent number: 8557280Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: GrantFiled: February 15, 2013Date of Patent: October 15, 2013Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8551521Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: GrantFiled: February 26, 2013Date of Patent: October 8, 2013Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8551975Abstract: An orally administered soft gelatin formulation preparation of low molecular weight Hyaluronic Acid (HA) for use as a nutritional supplement to provide the primary benefit of internally causing the softening of the human skin.Type: GrantFiled: October 10, 2006Date of Patent: October 8, 2013Assignee: Soft Gel Technologies, Inc.Inventors: Ronald G. Udell, Yousry M. A. Naguib
-
Publication number: 20130259933Abstract: The present invention is to obtain capsules which do not disintegrate in stomach and intestine after orally administrating them and which disintegrate specifically in large intestine. The present invention thus provides a capsule which disintegrates specifically in large intestine, comprising a content comprising a main agent, and a shell, covering the content, comprising a natural water-soluble polymer as a shell base material and chitosan powder dispersing in the natural water-soluble polymer.Type: ApplicationFiled: October 16, 2012Publication date: October 3, 2013Applicant: MORISHITA JINTAN CO., LTD.Inventors: Ryosei KAMAGUCHI, Masafumi MIZUTANI
-
Patent number: 8545879Abstract: The invention provides pharmaceutical compositions comprising a therapeutically effective amount of meloxicam, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical compositions are in the form of a fast disintegrating dosage form suitable for releasing meloxicam rapidly in the oral cavity. Also provided are processes for preparing a pharmaceutical composition of the invention. Further provided are methods of treating arthritis or pain in a subject in need thereof, the method comprising orally administering to the subject a therapeutically effective amount of a pharmaceutical composition according to the invention.Type: GrantFiled: August 31, 2010Date of Patent: October 1, 2013Assignees: Wilmington Pharmaceuticals, LLC, R.P. Scherer Techonologies, Inc.Inventors: David Allen Burns, Gregory Edward Neal
-
Publication number: 20130243854Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.Type: ApplicationFiled: February 25, 2013Publication date: September 19, 2013Applicant: ICEUTICA, INC.Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch
-
Patent number: 8535713Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].Type: GrantFiled: April 4, 2008Date of Patent: September 17, 2013Assignee: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Publication number: 20130236540Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: ApplicationFiled: March 22, 2013Publication date: September 12, 2013Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Patent number: 8529952Abstract: Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.Type: GrantFiled: January 13, 2010Date of Patent: September 10, 2013Assignee: EthypharmInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier, Pascal Oury, Keith S. Rotenberg, George Bobotas
-
Patent number: 8524280Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.Type: GrantFiled: December 15, 2009Date of Patent: September 3, 2013Assignee: Banner Pharmacaps, Inc.Inventors: Aqeel Fatmi, Tae Kyoung Kim, Karla E. Madrigal
-
Publication number: 20130224290Abstract: The present invention relates to an oral pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core containing duloxetine, an optional separating layer, an enteric layer and an optional finishing layer.Type: ApplicationFiled: May 25, 2010Publication date: August 29, 2013Applicant: HETERO RESEARCH FOUNDATIONInventors: Bandi Parthasaradhi Reddy, Podili Khadgapathi, Sanikommu Venkata Ramana Reddy, Kalidindi Praveen Kumar
-
Publication number: 20130224288Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.Type: ApplicationFiled: July 15, 2011Publication date: August 29, 2013Inventor: Michael Mutz
-
Patent number: 8518438Abstract: Liquid softgel fill formulations include (i) 26-32% by weight acetaminophen, (ii) 47-51% by weight polyethylene glycol having an average molecular weight of 200-800, (iii) 3-7% by weight propylene glycol, (iv) 9-13% by weight Povidone K17, and (v) 6-10% by weight purified water. The fill formulations are free of alkali metal ions. Also disclosed are a method of preparing the above-described fill formulations and softgel capsules containing the same fill formulations.Type: GrantFiled: December 15, 2011Date of Patent: August 27, 2013Assignee: Enspire Group, LLCInventors: Abdul Rashid, Minh Tran
-
Patent number: 8518439Abstract: A liquid composition includes a therapeutic component dispersed in a liquid carrier system. The liquid carrier system is made up of water and a solvent. The solvent includes at least 90 wt % propylene glycol and less than 2 wt % ethanol, if ethanol is present in the solvent. The therapeutic component has acetaminophen and phenylephrine. The weight ratio of solvent to phenylephrine is between 100:1 to 2000:1. The weight ratio of solvent to acetaminophen is between 5:1 and 25:1.Type: GrantFiled: December 3, 2009Date of Patent: August 27, 2013Assignee: Novartis AGInventors: Satisha Puttachari, Shripad Naik, Christopher Joseph Pulford
-
Publication number: 20130216483Abstract: A method of remotely treating an animal including launching a delivery system at the animal, wherein the delivery system comprises a dosage projectile adapted to deliver a biologically active agent to an animal substantially without piercing the skin of the animal and containing a biologically active agent and a transdermal carrier in liquid or gel form, wherein the agent and the carrier are encapsulated in one or more encapsulating agents, and wherein the encapsulating agents forms a frangible shell; impacting the projectile on the animal to release the biologically active agent and the transdermal carrier from the frangible shell substantially without piercing the skin of the animal; and delivering the biologically active agent to the animal, wherein the transdermal carrier facilitates passage of the biologically active agent across the skin of the animal to provide treatment to the animal.Type: ApplicationFiled: March 15, 2013Publication date: August 22, 2013Applicant: SMARTVET PTY LTD.Inventor: SmartVet Pty Ltd.
-
Publication number: 20130209569Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.Type: ApplicationFiled: January 25, 2013Publication date: August 15, 2013Applicant: iCeutica, Inc.Inventor: iCeutica, Inc.
-
Publication number: 20130209554Abstract: A gelatin capsule composition that includes one or more first distinct regions comprising a gelatin and one or more second distinct regions comprising a water-insoluble rapid-release agent is provided.Type: ApplicationFiled: June 29, 2012Publication date: August 15, 2013Applicant: GelitaInventors: Tom Keenan, John M. Dolphin
-
Publication number: 20130209556Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.Type: ApplicationFiled: March 12, 2013Publication date: August 15, 2013Applicants: Chrysalis Pharma AG, Omthera Pharmaceuticals, Inc.Inventors: Omthera Pharmaceuticals, Inc., Chrysalis Pharma AG
-
Publication number: 20130209555Abstract: The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4?-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.Type: ApplicationFiled: March 11, 2013Publication date: August 15, 2013Applicant: Vascular Biogenics Ltd.Inventor: Vascular Biogenics Ltd.
-
Patent number: 8506981Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.Type: GrantFiled: April 23, 2013Date of Patent: August 13, 2013Assignee: Synergy Biomedical LLPInventor: Mark D. Borden
-
Patent number: 8506859Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.Type: GrantFiled: February 28, 2012Date of Patent: August 13, 2013Assignee: Soft Gel Technologies, Inc.Inventor: Michael Fantuzzi
-
Patent number: 8506997Abstract: The present invention refers to a new compound containing Silymarin with Carbopol for the treatment of Diabetes Mellitus. This compound morphologically and structurally regenerates the damage that occurs in the pancreatic tissue in Diabetes Mellitus, and regenerates the insulin-producing pancreatic cells (? cells). It therefore regulates the serum levels of this hormone. Furthermore, it restores and maintains the normal concentrations of the blood glucose.Type: GrantFiled: May 1, 2009Date of Patent: August 13, 2013Assignee: Universidad Autonoma MetropolitanaInventor: Claudia Angelica Soto Peredo
-
Publication number: 20130202693Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic hydrophilic surfactant.Type: ApplicationFiled: June 1, 2011Publication date: August 8, 2013Applicant: ASTELLAS DEUTSCHLAND GMBHInventors: Jeffrey Colledge, Margaretha Olthoff
-
Publication number: 20130202692Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.Type: ApplicationFiled: April 22, 2011Publication date: August 8, 2013Inventors: Sharon Mates, Robert Davis, Lawrence P. Wennogle, Peng Li, John Charles Tomesch, Qiang Zhang
-
Patent number: 8501225Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: GrantFiled: September 13, 2012Date of Patent: August 6, 2013Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8497291Abstract: The present invention relates to a pharmaceutical formulation which comprises (i) a capsule, and (ii) a core comprising crystalline 2?-cyano-2?-deoxy-N4-palmitoyl-1-?-D-arabinofuranosylcytosine and a liquid carrier.Type: GrantFiled: December 22, 2006Date of Patent: July 30, 2013Assignee: Cyclacel LimitedInventors: Robert Westwood, Alistair Selkirk
-
Publication number: 20130189355Abstract: The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbA1c value of about 5.00%-8.50% or at least about 6.8%.Type: ApplicationFiled: January 7, 2013Publication date: July 25, 2013Applicant: Amarin Pharmaceuticals Ireland LimitedInventor: Amarin Pharmaceuticals Ireland Limited
-
Patent number: 8486445Abstract: The invention relates to a self-microemulsifying drug delivery system (“SMEDDS”) of mitotane, with enhanced bioavailability. More particularly the invention provides a mitotane oily formulation comprising propylene glycol monocaprylate (10 to 30% w/w), propylene glycol dicaprate (20 to 60% w/w) and polyoxyethylenesorbitanne monooleate (10 to 30% w/w).Type: GrantFiled: May 24, 2010Date of Patent: July 16, 2013Inventors: Florian Battung, Emad Hassan, Lionel Sansoe
-
Publication number: 20130177644Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.Type: ApplicationFiled: March 1, 2013Publication date: July 11, 2013Applicant: Celgene CorporationInventor: Celgene Corporation
-
Publication number: 20130177643Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.Type: ApplicationFiled: January 4, 2013Publication date: July 11, 2013Applicants: Chrysalis Pharma AG, Omthera Pharmaceuticals, Inc.Inventors: Omthera Pharmaceuticals, Inc., Chrysalis Pharma AG
-
Patent number: 8472986Abstract: Disclosed are a system, method, and article of manufacture for optimization of context-data acquisition by a mobile device. A term of a short message generated with a mobile device is identified. A list is populated with at least one sensor of the mobile device. The list is sorted according to a specified metric. A physical quantity of an environmental attribute of the mobile device is measured with a first listed sensor. The measurement is converted into a context data.Type: GrantFiled: July 16, 2010Date of Patent: June 25, 2013Assignee: Buckyball Mobile, Inc.Inventors: Amit Karmarkar, Richard Peters
-
Publication number: 20130149378Abstract: An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of ?-tocotrienol, ?-tocotrienol, ?-tocotrienol, or ?-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg ?-tocotrienol.Type: ApplicationFiled: February 7, 2013Publication date: June 13, 2013Applicant: DracoPharma, Inc.Inventor: Steven C. Quay